Allosteric Activation of MALT1 by Its Ubiquitin-Binding Ig3 Domain
Allosteric activation of MALT1 by its ubiquitin-binding Ig3 domain Rebekka Schairera,1, Gareth Hallb,c,1, Ming Zhanga,1,2, Richard Cowanb,c, Roberta Baravalleb,c, Frederick W. Muskettb,c, Peter J. Coombsd, Chido Mpamhangad, Lisa R. Haled, Barbara Saxtyd, Justyna Iwaszkiewicze, Chantal Décailleta, Mai Perrouda, Mark D. Carrb,c,3, and Margot Thomea,3 aDepartment of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland; bDepartment of Molecular and Cell Biology, University of Leicester, LE1 7RH Leicester, United Kingdom; cLeicester Institute of Structural and Chemical Biology, University of Leicester, LE1 7RH Leicester, United Kingdom; dLifeArc, Accelerator Building, Open Innovation Campus, SG1 2FX Stevenage, United Kingdom; and eSwiss Institute of Bioinformatics, 1015 Lausanne, Switzerland Edited by Tak W. Mak, University Health Network, Toronto, Canada, and approved December 30, 2019 (received for review July 23, 2019) The catalytic activity of the protease MALT1 is required for Using biochemical approaches, we have previously shown that adaptive immune responses and regulatory T (Treg)-cell develop- MALT1 activation requires its monoubiquitination on K644, a ment, while dysregulated MALT1 activity can lead to lymphoma. lysine residue situated at the surface of the Ig3 domain (15). MALT1 activation requires its monoubiquitination on lysine 644 Moreover, we demonstrated an interaction of ubiquitin with an (K644) within the Ig3 domain, localized adjacent to the protease unknown binding site within the C-terminal half of MALT1, which domain. The molecular requirements for MALT1 monoubiquitina- comprises the protease domain, the Ig3 domain, and a non- tion and the mechanism by which monoubiquitination activates structured C-terminal extension (15). However, the precise loca- MALT1 had remained elusive.
[Show full text]